Evidence map›Paper›PMID 39519803›Full record

ArticleMolecules (Basel, Switzerland)2024

A Highly Sensitive UPLC-MS/MS Method for the Quantification of the Organic Cation Transporters' Mediated Metformin Uptake and Its Inhibition in Cells.

Gzona Bajraktari-Sylejmani, Cindy Bay, Lukas Gebauer, Jürgen Burhenne, Johanna Weiss, Max Sauter

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gzona Bajraktari-SylejmaniInternal Medicine IX-Department of Clinical Pharmacology and Pharmacoepidemiology, Medical Clinic Heidelberg, Medical Faculty Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0001-7870-1542
Cindy BayInternal Medicine IX-Department of Clinical Pharmacology and Pharmacoepidemiology, Medical Clinic Heidelberg, Medical Faculty Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0003-3898-3148
Lukas GebauerInstitute of Clinical Pharmacology, University Medical Center Göttingen, 37075 Göttingen, Germany.ORCID 0000-0003-2823-4178
Jürgen BurhenneInternal Medicine IX-Department of Clinical Pharmacology and Pharmacoepidemiology, Medical Clinic Heidelberg, Medical Faculty Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-2190-1698
Johanna WeissInternal Medicine IX-Department of Clinical Pharmacology and Pharmacoepidemiology, Medical Clinic Heidelberg, Medical Faculty Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-2034-923X
Max SauterInternal Medicine IX-Department of Clinical Pharmacology and Pharmacoepidemiology, Medical Clinic Heidelberg, Medical Faculty Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0003-4977-1925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metformin is the gold standard substrate for evaluating potential inhibitors of the organic cation transporters (OCTs). Here, we established a UPLC-MS/MS assay to quantify metformin in cell pellets with a range of 0.05-50 ng/mL using 6-deuterated metformin as an internal standard. We used an ion-pairing chromatographic approach with heptafluorobutyric acid, making use of a reverse-phase column, and overcame the associated ion-suppression via previously established post-column injection of aqueous ammonia. The assay was validated according to the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recommendations for bioanalytical methods. The established extraction procedure was simple, very fast and ensured almost 100% recovery of the analyte. The exceptionally sharp peak form and retention of the ion-pairing chromatography are superior to other methods and allow us to measure as sensitively as 0.05 ng/mL. We used the herein established and validated method to develop a cellular OCT inhibition assay by using metformin as a substrate and human embryonic kidney cells (HEK) overexpressing the OCTs 1-3. The method presented may be useful for identifying new OCT inhibitors, but also for drug-drug interactions and other pharmacokinetic studies, where accurate quantification of low metformin amounts in relevant tissues is mandatory.

Indexed as

MetforminOrganic Cation Transport ProteinsTandem Mass SpectrometryBiological TransportChromatography, High Pressure LiquidHEK293 CellsHumansLiquid Chromatography-Mass SpectrometryMetforminOrganic Cation Transport ProteinsHEK293metforminOCTorganic cation transportersUPLC-MS/MSverapamil

Identifiers

PMID39519803
PMCPMC11547985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.